60864 Federal Register / Vol. 79, No. 195 / Wednesday, October 8, 2014 / Notices 

The Commission advises the 

Secretary and the NPS on matters 

relating to the management and 

development of Acadia National Park, 

including but not limited to the 

acquisition of lands and interests in 

lands (including conservation 

easements on islands) and the 

termination of rights of use and 

occupancy. 

The Commission is composed of 16 

members appointed by the Secretary, as 

follows: (a) Three members at large; (b) 

three members appointed from among 

individuals recommended by the 

Governor of Maine; (c) four members 

appointed from among individuals 

recommended by each of the four towns 

on the island of Mount Desert; (d) three 

members appointed from among 

individuals recommended by each of 

the three Hancock County mainland 

communities of Gouldsboro, Winter 

Harbor, and Trenton, and; (e) three 

members appointed from among 

individuals recommended by each of 

the three island towns of Cranberry 

Isles, Swans Island, and Frenchboro. 

Members of the Commission will 

receive no pay, allowances, or benefits 

by reason of their service on the 

Commission. However, while away from 

their homes or regular places of 

business in the performance of services 

for the Commission as approved by the 

Designated Federal Officer, members 

will be allowed travel expenses, 

including per diem in lieu of 

subsistence, in the same manner as 

persons employed intermittently in 

Government service are allowed such 

expenses under 5 U.S.C. 5703. 

Individuals who are Federally 

registered lobbyists are ineligible to 

serve on all FACA and non-FACA 

boards, committees, or councils in an 

individual capacity. The term 

‘‘individual capacity’’ refers to 

individuals who are appointed to 

exercise their own individual best 

judgment on behalf of the government, 

such as when they are designated 

Special Government Employees, rather 

than being appointed to represent a 

particular interest. 

Seeking Nominations for Membership 

We are seeking nominations for 

commission members in the following 

category: Members at large. 

Nominations should include a resume 

providing an adequate description of the 

nominee’s qualifications, including 

information that would enable the 

Department of the Interior to make an 

informed decision regarding meeting the 

membership requirements of the 

Commission and permit the Department 

to contact a potential member. 

Members are appointed by the 

Secretary for a term not to exceed three 

years. The terms of the three members 

at large of the Commission expire on 

September 28, 2014. The Commission 

last met on June 2, 2014, and usually 

meets three times per year, generally in 

June, September, and February. 

Meetings may take place at such times 

as designated by the Designated Federal 

Officer. Members are expected to make 

every effort to attend all meetings. 

Members may not appoint deputies or 

alternates. 

Dated: September 26, 2014. 

Alma Ripps, 

Chief, Office of Policy. 

[FR Doc. 2014–24044 Filed 10–7–14; 8:45 am] 

BILLING CODE 4310–EE–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Fisher Clinical Services, 

Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration in 

accordance with 21 CFR 1301.34(a) on 

or before November 7, 2014. Such 

persons may also file a written request 

for a hearing on the application 

pursuant to 21 CFR 1301.43 on or before 

November 7, 2014. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/ODW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. Request for hearings should be 

sent to: Drug Enforcement 

Administration, Attention: Hearing 

Clerk/LJ, 8701 Morrissette Drive, 

Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of importers, 

of controlled substances (other than 

final orders in connection with 

suspension, denial, or revocation of 

registration) has been redelegated to the 

Deputy Assistant Administrator of the 

DEA Office of Diversion Control 

(‘‘Deputy Assistant Administrator’’) 

pursuant to section 7 of 28 CFR part 0, 

subpart R, App. 

In accordance with 21 CFR 

1301.34(a), this is notice that on 

December 13, 2013, Fisher Clinical 

Services, Inc., 700A–C Nestle Way, 

Breinigsville, Pennsylvania 18031–1522 

applied to be registered as an importer 

of the following basic classes of 

controlled substances: 

Controlled substance Schedule 

Methylphenidate (1724) ................ II 

Levorphanol (9220) ...................... II 

Noroxymorphone (9668) .............. II 

Tapentadol (9780) ........................ II 

The company plans to import the 

listed substances for analytical research, 

testing, and clinical trials. This 

authorization does not extend to the 

import of a finished FDA approved or 

non-approved dosage form for 

commercial distribution in the United 

States. 

The company plans to import an 

intermediate form of tapentadol (9780) 

to bulk manufacture tapentadol for 

distribution to its customers. 

Dated: October 1, 2014. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2014–24081 Filed 10–7–14; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Registration: Alkermes Gainesville 

LLC 

ACTION: Notice of registration. 

SUMMARY: Alkermes Gainesville LLC 

applied to be registered as an importer 

of a basic class of controlled substance. 

The DEA grants Alkermes Gainesville 

LLC registration as an importer of this 

controlled substance. 

SUPPLEMENTARY INFORMATION: By notice 

dated June 10, 2014, and published in 

the Federal Register on June 17, 2014, 

79 FR 34551, Alkermes Gainesville LLC, 

1300 Gould Drive, Gainesville, Georgia 

30504, applied to be registered as an 

importer of a certain basic class of 

controlled substance. No comments or 

objections were submitted for this 

notice. 

The Drug Enforcement 

Administration (DEA) has considered 


asabaliauskas on DSK5VPTVN1PROD with NOTICES
Federal Register / Vol. 79, No. 195 / Wednesday, October 8, 2014 / Notices 60865 

the factors in 21 U.S.C. 823,952(a) and 

958(a) and determined that the 

registration of Alkermes Gainesville LLC 

to import the basic class of controlled 

substance is consistent with the public 

interest and with United States 

obligations under international treaties, 

conventions, or protocols in effect on 

May 1, 1971. The DEA investigated the 

company’s maintenance of effective 

controls against diversion by inspecting 

and testing the company’s physical 

security systems, verifying the 

company’s compliance with state and 

local laws, and reviewing the company’s 

background and history. 

Therefore, pursuant to 21 U.S.C. 

952(a) and 958(a), and in accordance 

with 21 CFR 1301.34, the above-named 

company is granted registration as an 

importer of Noroxymorphone (9668), a 

basic class of controlled substance listed 

in schedule II. 

The company plans to import the 

above listed controlled substance for 

analytical research and testing. 

The import of the above listed basic 

class of controlled substance would be 

granted only for analytical testing and 

clinical testing. This authorization does 

not extend to the import of a finished 

FDA approved or non-approved dosage 

form for commercial distribution in the 

United States. 

Dated: October 1, 2014. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2014–24032 Filed 10–7–14; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Manufacturer of Controlled 

Substances Registration: Austin 

Pharma, LLC 

ACTION: Notice of registration. 

SUMMARY: Austin Pharma, LLC applied 

to be registered as a manufacturer of 

certain basic classes of controlled 

substances. The DEA grants Austin 

Pharma, LLC registration as a 

manufacturer of those controlled 

substances. 

SUPPLEMENTARY INFORMATION: By notice 

dated May 28, 2014, and published in 

the Federal Register on June 4, 2014, 79 

FR 32322, Austin Pharma, LLC, 811 

Paloma Drive, Suite C, Round Rock, 

Texas 78665–2402, applied to be 

registered as a manufacturer of certain 

basic classes of controlled substances. 

No comments or objections were 

submitted to this notice. 

The Drug Enforcement 

Administration (DEA) has considered 

the factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Austin Pharma, LLC to manufacture the 

basic classes of controlled substances is 

consistent with the public interest and 

with United States obligations under 

international treaties, conventions, or 

protocols in effect on May 1, 1971. The 

DEA investigated the company’s 

maintenance of effective controls 

against diversion by inspecting and 

testing the company’s physical security 

systems, verifying the company’s 

compliance with state and local laws, 

and reviewing the company’s 

background and history. 

Therefore, pursuant to 21 U.S.C. 

823(a), and in accordance with 21 CFR 

1301.33, the above-named company is 

granted registration as a bulk 

manufacturer of the basic classes of 

controlled substances: 

Controlled substance Schedule 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

The company plans to manufacture 

bulk synthetic active pharmaceutical 

ingredients (APIs) for distribution and 

new product development to its 

customers. The company plans to bulk 

manufacture a synthetic 

tetrahydrocannabinol. 

In reference to drug code 7360, the 

company plans to manufacture a 

synthetic cannabinol in bulk for sale to 

its customers. The controlled substance 

will be further synthesized to bulk 

manufacture a synthetic 

tetrahydrocannabinol (7370). No other 

activity for this drug code is authorized 

for this registration. 

Dated: October 2, 2014. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2014–24018 Filed 10–7–14; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Manufacturer of Controlled 

Substances Registration: Siemens 

Healthcare Diagnostics, Inc. 

ACTION: Notice of registration. 

SUMMARY: Siemens Healthcare 

Diagnostics, Inc., applied to be 

registered as a manufacturer of certain 

basic classes of controlled substances. 

The DEA grants Siemens Healthcare 

Diagnostics, Inc. registration as a 

manufacturer of those controlled 

substances. 

SUPPLEMENTARY INFORMATION: By notice 

dated May 2, 2014, and published in the 

Federal Register on May 15, 2014, 79 

FR 27936, Siemens Healthcare 

Diagnostics, Inc., Attn: RA, 100 GBC 

Drive, Mailstop 514, Newark, Delaware 

19702, applied to be registered as a 

manufacturer of certain basic classes of 

controlled substances. No comments or 

objections were submitted to this notice. 

The Drug Enforcement 

Administration (DEA) has considered 

the factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Siemens Healthcare Diagnostics, Inc., to 

manufacture the basic classes of 

controlled substances is consistent with 

the public interest and with United 

States obligations under international 

treaties, conventions, or protocols in 

effect on May 1, 1971. The DEA 

investigated the company’s maintenance 

of effective controls against diversion by 

inspecting and testing the company’s 

physical security systems, verifying the 

company’s compliance with state and 

local laws, and reviewing the company’s 

background and history. 

Therefore, pursuant to 21 U.S.C. 

823(a), and in accordance with 21 CFR 

1301.33, the above-named company is 

granted registration as a bulk 

manufacturer of the basic classes of 

controlled substances listed: 

Controlled substance Schedule 

Tetrahydrocannabinols (7370) ..... I 

Ecgonine (9180) ........................... II 

Morphine (9300) ........................... II 

The company plans to produce the 

listed controlled substances in bulk to 

be used in the manufacture of reagents 

and drug calibrator controls which are 

DEA exempt products. 

In reference to drug code 7370 the 

company plans to bulk manufacture a 

synthetic tetrahydrocannabinol. No 

other activity for this drug code is 

authorized for this registration. 

Dated: October 1, 2014. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator. 

[FR Doc. 2014–24035 Filed 10–7–14; 8:45 am] 

BILLING CODE 4410–09–P 


asabaliauskas on DSK5VPTVN1PROD with NOTICES